Alefacept, which targets CD2 primarily expressed on CD4+ and CD8+ effector memory T cells, has been tested in recent-onset T1D and displayed C-peptide preservation along with reduced use of exogenous insulin compared to a placebo group (272, 273). The gene discussed is INS; the disease is type 1 diabetes mellitus.